• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

    9/9/25 5:30:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care
    Get the next $OSRH alert in real time by email

    BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (NASDAQ:OSRH) today announced that on September 5, 2025, it received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

    OSR Holdings logo (PRNewsfoto/OSR Holdings)

    The notice does not affect the listing of OSR Holdings' common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." In accordance with Nasdaq rules, the Company has until March 4, 2026 to regain compliance.

    Despite recent share price volatility, OSR Holdings continues to believe that its market value does not reflect the strength of its business fundamentals or the momentum across its programs. The Company continues to:

    • Advance its portfolio of transformative programs in key therapeutic areas including oral immunotherapies and regenerative medicine.
    • Build its Digital Asset Treasury (DAT) strategy to reinforce financial flexibility and resilience.
    • Conduct due diligence on Woori IO, a developer of non-invasive glucose monitoring technology, underscoring a commitment to advancing high-impact, complementary innovations.

    While executing these strategic initiatives, the Company has also observed trading activities in its shares that appear inconsistent with underlying fundamentals. Publicly available SEC fails-to-deliver (FTD) data has reflected significantly elevated levels of settlement imbalances in OSRH on notable dates marked by high trading volatility, heavy volumes, or material press releases such as M&A term sheet announcements. The Company believes this data may indicate the presence of manipulative short selling practices that have contributed to downward pressure on its share price.

    "Our focus remains firmly on advancing our scientific programs and creating long-term value for our stakeholders," said Peter Hwang, Chief Executive Officer of OSR Holdings. "We take market integrity very seriously, and we will continue to pursue both operational execution and proactive measures to address unusual trading dynamics."

    OSR Holdings is committed to protecting the interests of all shareholders. The Company intends to actively monitor trading activity, engage with regulators as appropriate, and evaluate all available options to ensure a fair and orderly market for its securities.

    "OSR Holdings is built on strong scientific foundations, a diversified innovation pipeline, and forward-looking strategies such as our digital asset treasury initiatives," added Tim Smith, Head of Global Investor Relations. "We remain confident in the long-term value of our business, and while we are committed to addressing unusual trading dynamics, our priority is to continue advancing programs that can make a meaningful difference for patients and shareholders alike."

    About OSR Holdings

    OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit www.OSR‑Holdings.com.

    Contact

    Investor Relations

    OSR Holdings, Inc.

    Email: ir@osr‑holdings.com

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding the Company's ability to regain compliance with Nasdaq listing standards, its development pipeline, digital asset treasury strategy, and due diligence activities with Woori IO. These statements are subject to risks and uncertainties, and actual results may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-receives-nasdaq-minimum-bid-price-deficiency-notice-company-highlights-unusual-trading-activity-302551528.html

    SOURCE OSR Holdings

    Get the next $OSRH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSRH
    SEC Filings

    View All

    OSR Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    10/16/25 11:10:18 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by OSR Holdings Inc.

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    9/23/25 8:40:55 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    9/9/25 4:47:39 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

    BELLEVUE, Wash., Oct. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

    10/14/25 8:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

    BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (NASDAQ:OSRH) today announced that on September 5, 2025, it received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The notice does not affect the listing of OSR Holdings' common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." In accordance with Nasdaq rules, the Company has until Marc

    9/9/25 5:30:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

    BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a  global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH

    8/1/25 1:29:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fierz Reto Kaspar

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    10/24/25 12:58:23 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Leadership Updates

    Live Leadership Updates

    View All

    OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

    BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

    7/15/25 7:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

    BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a

    3/25/25 7:00:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care